Media Hub

Feb 2020

New gene therapy to halt rare inherited eye disorder

It is hoped that the new treatment, Luxturna, which costs around £600,000 and has been approved by the National Institute for Health and Care Excellence, will improve vision and even halt sight loss. The gene therapy will benefit patients who have retinal dystrophy, a condition which stems from inheriting a faulty copy of the RPE65…

Read More

Feb 2019

Gene therapy successfully stops most common cause of blindness

A patient in the UK has become the first in the world to undertake gene therapy in an attempt to stop the most common form of blindness in the western world, targeting the underlying genetic cause of age-related macular degeneration (AMD). Around 600,000 people in the UK are currently affected by the condition, where retinal…

Read More